Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The Tuberculosis Drug Accelerator at year 10: what have we learned?

The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for the application of similar models to other diseases.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Overview of TBDA activities.


  1. Conradie, F. et al. N. Engl. J. Med. 382, 893–902 (2020).

    Article  CAS  Google Scholar 

  2. Early, J. et al. ACS Infect. Dis. 5, 272–280 (2019).

    Article  CAS  Google Scholar 

  3. VanderVen, B. C. et al. PLoS Pathog. 11, e1004679 (2015).

    Article  Google Scholar 

  4. Warrier, T. et al. ACS Infect. Dis. 1, 580–585 (2015).

    Article  CAS  Google Scholar 

  5. Kim, J. H. et al. Proc. Natl Acad. Sci. USA 110, 19095–19100 (2013).

    Article  CAS  Google Scholar 

  6. Ballinger, E. et al. Science 363, eaau8959 (2019).

    Article  CAS  Google Scholar 

  7. Blanc, L. et al. eLife 7, e41115 (2018).

    Article  Google Scholar 

  8. Tasneen, R. et al. Antimicrob. Agents Chemother. 60, 270–277 (2016).

    Article  CAS  Google Scholar 

  9. Via, L. E. et al. ACS Infect. Dis. 1, 203–214 (2015).

    Article  CAS  Google Scholar 

  10. Prideaux, B. et al. Nat. Med. 21, 1223–1227 (2015).

    Article  CAS  Google Scholar 

  11. Sarathy, J. P. et al. ACS Infect. Dis. 2, 552–563 (2016).

    Article  CAS  Google Scholar 

  12. Strydom, N. et al. PLoS Med. 16, e1002773 (2019).

    Article  CAS  Google Scholar 

  13. Chakraborty, S., Gruber, T., Barry, C. E. III, Boshoff, H. I. & Rhee, K. Y. Science 339, 88–91 (2013).

    Article  CAS  Google Scholar 

  14. Wang, Z. et al. Proc. Natl Acad. Sci. USA 116, 19646–19651 (2019).

    Article  CAS  Google Scholar 

  15. Cokol, M., Kuru, N., Bicak, E., Larkins-Ford, J. & Aldridge, B. B. Sci. Adv. 3, e1701881 (2017).

    Article  Google Scholar 

  16. Ballell, L. et al. ChemMedChem 8, 313–321 (2013).

    Article  CAS  Google Scholar 

  17. Diacon, A. H. et al. N. Engl. J. Med. 375, 393–394 (2016).

    Article  Google Scholar 

  18. Aggarwal, A. et al. Cell 170, 249–259.e225 (2017).

    Article  CAS  Google Scholar 

  19. Ray, P. C. et al. ACS Omega 6, 2284–2311 (2021).

    Article  CAS  Google Scholar 

  20. Chengalroyen, M. D. et al. Front. Cell. Infect. Microbiol. 10, 582416 (2020).

    Article  CAS  Google Scholar 

  21. Xu, J. et al. Antimicrob. Agents Chemother. 65, e02418 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Tiwari, D. et al. Sci. Transl. Med. 10, eaal1803 (2018).

    Article  Google Scholar 

  23. Evans, J. C. et al. ACS Infect. Dis. 2, 958–968 (2016).

    Article  CAS  Google Scholar 

  24. Beites, T. et al. Nat. Commun. 10, 4970 (2019).

    Article  Google Scholar 

  25. Berube, B.J. et al. Antimicrob. Agents Chemother. (2019).

  26. Smith, J. et al. Medchemcomm 10, 934–945 (2019).

    Article  CAS  Google Scholar 

  27. Park, Y. et al. ACS Infect. Dis. 3, 18–33 (2017).

    Article  CAS  Google Scholar 

  28. Marakalala, M. J. et al. Nat. Med. 22, 531–538 (2016).

    Article  CAS  Google Scholar 

  29. Cox, J. A. et al. New Microbiol. 1, 15006 (2016).

    CAS  Google Scholar 

  30. Wang, Q. et al. Science 367, 1147–1151 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations



C.E.B., R.H.B., S.J.B., K.D., N.F., V.M., C.N., B.R. and P.W. served as the drafting committee; C.E.B. prepared the figure with assistance from B.B.A., H.I.B., V.D., K.D., K.Y.R. and J.C.S.; and D.B.-A., K.C., X.-J.C., C.B.C., F.G., P.A.H., D.J.., J.L., A.J.L., C.W.M., D.B.O., T.P., H.M.P., A.P., G.T.R., J.M.R., E.J.R., D.G.R., D.S., M.S., A.M.U., P.G.W. and Y.Y. contributed comments.

Corresponding author

Correspondence to Carl Nathan.

Ethics declarations

Competing interests

D.B.-A., R.H.B. and J.L. are employed by GlaxoSmithKline; F.G. is employed by Eisai; P.A.H. is employed by Lgenia; D.J.K. and M.S. are employed by AbbVie; D.B.O. is employed by Merck & Co.; H.M.P. is employed by Calibr; A.P. is employed by Janssen-Cilag; and A.M.U. is employed by Evotec.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aldridge, B.B., Barros-Aguirre, D., Barry, C.E. et al. The Tuberculosis Drug Accelerator at year 10: what have we learned?. Nat Med 27, 1333–1337 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research